
By Craig Tallentire

Genesis Research Group (Genesis) launches Keystone, its modular platform for Integrated Evidence Generation Planning (IEGP), at ISPOR Europe 2026.
Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will...

The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....

An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease

Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer

Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...

The treatments are for eligible adults in England and Wales

A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.